Metoject Pen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing tetrahydrofolate availability. This limits the synthesis of purine and pyrimidine nucleotides, which are essential for DNA, RNA and protein production, thereby suppressing immune cell activity and slowing the growth of malignant cells.

The dose of Metoject Pen is individualized by the prescribing clinician based on the specific condition, disease severity, patient weight, renal and hepatic function, and response to therapy. No fixed dosing regimen is provided here; the prescriber sets the appropriate amount.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To request Metoject Pen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metoject Pen (methotrexate) is a conventional disease‑modifying antirheumatic drug (DMARD) and differs from biologic agents such as TNF‑alpha inhibitors. While biologics target specific cytokines, methotrexate broadly suppresses immune cell proliferation. It is generally less expensive but requires careful monitoring for toxicity.

Metoject Pen should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the pen in its original packaging until use to maintain stability and prevent contamination.

Metoject Pen is a pre‑filled, single‑use device designed for subcutaneous injection. The user selects the prescribed dose, cleans the injection site, inserts the needle, and presses the plunger to deliver the medication. Proper technique and disposal of the pen are essential.

Serious adverse events include severe liver toxicity, bone‑marrow suppression leading to pancytopenia, pulmonary fibrosis or interstitial pneumonitis, and life‑threatening infections due to immunosuppression. Patients should be monitored regularly for signs of these complications.

Metoject Pen is contraindicated in pregnant or breastfeeding individuals, patients with severe hepatic or renal impairment, active uncontrolled infections, and those with known hypersensitivity to methotrexate or any component of the pen. Caution is also advised for patients with pre‑existing lung disease.